FDA Puts Cancer Risk Predictors into Safer Class II Category
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting cancer risk assessment systems into a safer, more controlled category called Class II. This means these devices will have special rules to make sure they work well and keep patients safe. This change helps people get better access to new, helpful tools without unnecessary delays or costs.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Cancer Risk Tests Moved to Safer Category
The FDA is placing cancer predisposition risk assessment systems into Class II (special controls). The Agency says this classification provides a reasonable assurance of safety and effectiveness and will enhance patient access by reducing regulatory burdens for these devices.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11429 — Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that Protamine Sulfate and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. Patients and pharmacies can keep counting on these medicines without any interruptions or extra costs.
2026-11308 — Medical Devices; Orthopedic Devices; Classification of the Resorbable Calcium Salt Bone Void Filler Containing a Single Approved Aminoglycoside Antibacterial
The FDA is officially putting a special bone filler that slowly dissolves and fights bacteria into a safer, easier-to-manage category called Class II. This change helps make sure the product is safe and effective while speeding up patient access to this cool new tech. It’s been in effect since May 2022, so companies and patients can expect smoother approvals and fewer hoops to jump through.
2026-11302 — Medical Devices; Orthopedic Devices; Classification of the Absorbable Metallic Bone Fixation Fastener
The FDA is officially classifying absorbable metallic bone fixation fasteners as Class II devices with special safety rules, making them easier to get to patients while keeping them safe and effective. This change helps doctors and patients by reducing red tape and encouraging new, helpful bone-fixing tech. The new rules took effect on June 5, 2026, but have been in place since March 29, 2023, so manufacturers should already be on board.
2026-11306 — Medical Devices; Orthopedic Devices; Classification of the Shoulder Joint Humeral (Hemi-Shoulder) Ceramic Head/Metallic Stem Cemented or Uncemented Prosthesis
The FDA is officially putting the shoulder joint humeral ceramic head/metallic stem prosthesis into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps patients get safer, innovative shoulder implants faster and makes life easier for makers by lowering regulatory costs. The new classification is effective June 5, 2026, but has been in effect since December 16, 2022.
2026-11303 — Intent To Exempt Certain Unclassified Medical Devices From Premarket Notification Requirements; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA is planning to exempt some unclassified medical devices from the usual premarket notification rules, making it easier and faster for these devices to reach the market. This change affects manufacturers of certain medical devices and could save them time and money. The new guidance is effective starting June 5, 2026, but the FDA is still open to feedback from the public.
2026-11062 — Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
Previous / Next Documents
Previous: 2025-16034 — Medical Devices; Immunology and Microbiology Devices; Classification of A Multiplex Respiratory Panel To Detect and Identify Emerging Respiratory Pathogen(s) and Common Respiratory Pathogens in Human Clinical Specimens
The FDA is officially classifying a new multiplex respiratory panel as a Class II device, meaning it has special safety rules to follow. This device helps doctors quickly spot both common and new respiratory germs in patient samples. This change makes it safer and easier for patients to get access to these helpful tests without extra delays or costs.
Next: 2025-16036 — Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Menopause Test System
The FDA is officially putting menopause test systems into a special safety group called Class II to make sure they work well and are safe. This change helps companies bring better menopause tests to patients faster and with fewer hoops to jump through. If you make or use these tests, expect smoother rules soon, helping everyone get reliable results without extra costs or delays.